Equities Analysts Offer Predictions for SLNO Q1 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – HC Wainwright dropped their Q1 2025 EPS estimates for Soleno Therapeutics in a report released on Monday, March 3rd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.83) per share for the quarter, down from their previous forecast of ($0.71). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q2 2025 earnings at ($0.84) EPS, Q3 2025 earnings at ($0.84) EPS, Q4 2025 earnings at ($0.83) EPS and FY2025 earnings at ($3.34) EPS.

Other analysts have also recently issued reports about the stock. Stifel Nicolaus initiated coverage on shares of Soleno Therapeutics in a research note on Wednesday. They set a “buy” rating and a $74.00 price target on the stock. Robert W. Baird reiterated an “outperform” rating and issued a $72.00 target price on shares of Soleno Therapeutics in a research note on Monday, December 2nd. Finally, Lifesci Capital upgraded shares of Soleno Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 4th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $71.20.

Soleno Therapeutics Stock Down 0.1 %

SLNO opened at $44.94 on Thursday. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -13.54 and a beta of -1.46. Soleno Therapeutics has a twelve month low of $36.61 and a twelve month high of $60.92. The company’s 50-day moving average price is $47.16 and its two-hundred day moving average price is $49.83.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.41).

Institutional Investors Weigh In On Soleno Therapeutics

Large investors have recently added to or reduced their stakes in the company. AlphaQuest LLC lifted its position in shares of Soleno Therapeutics by 1,154.4% in the 4th quarter. AlphaQuest LLC now owns 715 shares of the company’s stock worth $32,000 after purchasing an additional 658 shares during the period. US Bancorp DE purchased a new stake in shares of Soleno Therapeutics in the 4th quarter worth about $34,000. Avanza Fonder AB purchased a new stake in shares of Soleno Therapeutics in the 4th quarter worth about $76,000. Springhill Fund Asset Management HK Co Ltd purchased a new stake in shares of Soleno Therapeutics in the 4th quarter worth about $81,000. Finally, Avior Wealth Management LLC purchased a new stake in shares of Soleno Therapeutics in the 4th quarter worth about $89,000. Institutional investors own 97.42% of the company’s stock.

Insider Transactions at Soleno Therapeutics

In related news, CFO James H. Mackaness sold 4,083 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total transaction of $185,409.03. Following the transaction, the chief financial officer now owns 115,089 shares of the company’s stock, valued at approximately $5,226,191.49. This trade represents a 3.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bhatnagar Anish sold 10,937 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total transaction of $496,649.17. Following the transaction, the chief executive officer now directly owns 708,616 shares in the company, valued at approximately $32,178,252.56. This represents a 1.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 17,360 shares of company stock valued at $790,119 in the last quarter. Insiders own 12.30% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.